Category
152 releases
- Tome Skincare featured in Cosmopolitan, Women's Wear Daily, AIR MAIL, and Thingtesting highlights Tome's growing recognition among leading beauty…
Recognition highlights Renew's NeuroLens™ platform and its approach to investigating cell-type-specific biomarkers for neurodegenerative disease…
Erler, Senior Vice President of Patient Affairs at Sarepta Therapeutics, will advise Astrosalva on patient and community engagement and…
A small subset of vulnerable DNA sites can make cancer cells highly sensitive to targeted drugs called PARP inhibitors, a new study shows. Led by…
- Management conference call at 8:30 a.m. ET today -
Phase 1a study in healthy volunteers will assess safety, pharmacokinetics and pathway engagement; Phase 1b study in patients with advanced solid…
Golidocitinib monotherapy showed high and durable response in adults with secondary HLH, to be featured in an oral presentation. Two oral…
New data demonstrates the potential of longitudinal plasma proteomics to detect disease progression ahead of radiologic assessment and predict…
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody…
Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA…
Thera4Care is an initiative aimed at establishing an integrated theranostics ecosystem to broaden patient access in Europe Telix's fibroblast…
Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or…
Powered by eūvita Health, the educational platform provides scientifically reviewed information on peptide therapies, metabolic health, hormone…
Agreement brings preferred RCM pricing, network-wide KPI initiatives and shared operational best practices to Clarion member practices within ONCare…
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right…
Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG)…
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive…
Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test PreTRM® test…
PAPZIMEOS® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 bringing launch-to-date net product revenue to…
